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Abstract: SARS-CoV-2 is causing a pandemic resulting in high morbidity and mortality. COVID-19
patients suffering from acute respiratory distress syndrome (ARDS) are often critically ill and
show lung injury and hemolysis. Heme is a prosthetic moiety crucial for the function of a wide
variety of heme-proteins, including hemoglobin and cytochromes. However, injury-derived free
heme promotes adhesion molecule expression, leukocyte recruitment, vascular permeabilization,
platelet activation, complement activation, thrombosis, and fibrosis. Heme can be degraded by
the anti-inflammatory enzyme heme oxygenase (HO) generating biliverdin/bilirubin, iron/ferritin,
and carbon monoxide. We therefore postulate that free heme contributes to many of the inflammatory
phenomena witnessed in critically ill COVID-19 patients, whilst induction of HO-1 or harnessing heme
may provide protection. HO-activity not only degrades injurious heme, but its effector molecules
possess also potent salutary anti-oxidative and anti-inflammatory properties. Until a vaccine against
SARS-CoV-2 becomes available, we need to explore novel strategies to attenuate the pro-inflammatory,
pro-thrombotic, and pro-fibrotic consequences of SARS-CoV-2 leading to morbidity and mortality.
The heme-HO system represents an interesting target for novel “proof of concept” studies in the
context of COVID-19.
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1. COVID-19 Infection May Result in Severe Inflammatory Complications
SARS-CoV-2 is causing a pandemic health issue, affecting millions of people and resulting
in high morbidity and mortality. This virus is thought to specifically enter cells expressing the
angiotensin-converting enzyme-2 (ACE2) receptors at their cell surface, such as cells in the nose, lungs,
intestines, and kidneys [1–3]. Major common symptoms include fever, a dry cough, dyspnea, fatigue,
and myalgia [4]. Minor common symptoms include expectoration, anorexia, chest tightness, nausea
and vomiting, headache, pharyngalgia, shivering, and rhinorrhea [4].
Shortly following invasion of SARS-CoV-2 into the lungs, excessive pulmonary edema occurs as a
consequence of vascular leakage. Disruption of the alveolar–epithelial barrier hampers optimal gas
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exchange [5], resulting in dyspnea. The majority of hospitalized Covid-19 patients also experience
acute respiratory distress syndrome (ARDS), which appears to have various clinical features different
from typical ARDS [6,7]. This is accompanied by other problems, including vascular inflammation,
leukocyte recruitment, tissue injury, and the increased expression of interleukin-6, C-reactive protein,
ferritin, and tissue factor [8]. In addition to these inflammatory insults, fibrin formation, microthrombi,
and angiopathy develop that may result in vascular obstruction and fibrosis [9,10]. In addition to
pulmonary damage, other organs with ACE2-positive cells may be affected, causing gastro-intestinal
problems, multi-organ damage, and can ultimately even result in death.
In the absence of a vaccine against SARS-CoV-2, treatment is mainly supportive. In the meantime,
we should develop hypotheses and perform “proof of principle” studies aimed at preventing or
attenuating the complications leading to severe morbidity and death.
2. Can Injury-Derived Free Heme Contribute to COVID-19 Pathogenesis by Promoting
Inflammation, Vascular Permeabilization and Thrombosis?
Heme is the functional group of a variety of heme–proteins, including cytochromes and hemoglobin
(Hb), and is therefore crucial for many different cellular processes [11]. Excess of free heme has been
shown to exacerbate and contribute to the pathogenesis of a wide variety of inflammatory diseases and
conditions, such as sepsis, malaria, sickle cell disease, kidney disease, and multi-organ failure [11–15].
Additionally, within the lungs, free Hb and heme may be detrimental [16]. Chronic obstructive
pulmonary disease (COPD) patients show increased cell-free Hb, correlating with disease severity [17].
In addition, ARDS patients exhibit alveolar hemorrhage and high levels of erythrocytes, hemolysis,
and Hb in their pulmonary edema fluid [16,18–21]. Unfortunately, it is still not well understood how
these erythrocytes enter the alveolar space [16]. This could occur via active transport, by increased
endothelial and epithelial permeability, or by pronounced local vascular injury [16].
COVID-19 patients suffering from ARDS are critically ill and show also signs of hemolysis [22,23].
SARS-CoV-2 causes lung injury, resulting in death of inflammatory cells and sloughing of epithelial
alveolar cells, the pulmonary vasculature, and hemolysis. Other COVID-19 patients display additional
signs of tissue injury such as hemoptysis [24] or rhabdomyolysis [25], which may cause further cellular
damage and release of heme-proteins and accumulation of free heme.
This made us to postulate that hemolysis-derived heme could initiate or contribute to many of the
inflammatory phenomena witnessed in critically ill COVID-19 patients.
We and others previously demonstrated that excess free heme promotes oxidative and
inflammatory stress [26–29], activates the vascular endothelium, and increases adhesion molecules and
leukocyte recruitment [28,30]. Using radiolabeled liposomes, we further demonstrated that free heme
causes vascular permeabilization resulting in edema [28]. Accumulated free heme and Hb may thus
act as pathophysiologic mechanisms mediating pulmonary permeability and inflammation [31,32].
Alveolar fluid clearance is hampered in ARDS and also likely in hospitalized COVID-19 patients.
Intratracheal administration of heme causes alveolar-capillary barrier dysfunction, and increases
alveolar permeability, contributing to acute lung injury in mice [19]. Heme was shown to increase
pulmonary edema by inhibiting amiloride-sensitive epithelial Na+ channel (ENaC)-activity, which
plays a crucial role in sodium transport and fluid reabsorption in the lung [33].
Coagulation abnormalities, complement activation, endotheliitis, and thrombosis occur frequently
in COVID-19 patients [34–36]. Interestingly, heme also promotes platelet activation, complement
activation, vasculitis, and thrombosis [28,37–39]. Heme was recognized to act as a danger signal,
damage-associated molecular pattern (DAMP), or alarmin [11,30,40–42] and was shown to activate
Toll-like receptor 4 (TLR4) signaling [43]. Free heme promotes also oxidative stress by catalyzing the
Fenton reaction [44,45], scavenges nitric oxide (NO) [46], and activates the inflammasome via TLR4 and
NLR family pyrin domain containing 3 (NLPR3) [47,48]. In addition to heme promoting the expression
of inflammatory cytokines [49], it potentiates tumor necrosis factor (TNF)-alpha induced inflammatory
events and apoptosis [50].
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The deleterious actions of heme could explain many of the observed manifestations during
SARS-CoV-2 infection, including the increased capillary leakage resulting in pulmonary edema,
vasculitis, leukocyte recruitment, and thrombus formation.
3. Protective Mechanisms against Free Heme
In order to attenuate these heme-induced pro-inflammatory, pro-oxidative, and pro-thrombotic
actions, our body is normally equipped with different defense mechanisms. Following hemolysis,
Hb is released that can be scavenged by serum haptoglobin (Hp). Free Hb outside the erythrocyte will
turn into methemoglobin, which readily liberates its heme group [51]. Normally, this free heme gets
scavenged by hemopexin (hpx) to prevent its injurious actions [52,53]. In case of severe hemolysis,
or in blood clots, the hemoglobin and heme scavengers may be overwhelmed, exhausted, or physically
not able to interact and neutralize free Hb and heme.
Alternative protective mechanisms against free heme are then pivotal for cellular survival.
When heme enters the cell, it can modify proteins, DNA, and lipids [16,54,55]. Heme can also be
transported out of the cell by Breast Cancer Resistance Protein (BCRP) that increases its chance
of survival [56]. Finally, heme can be intracellularly degraded by heme oxygenase (HO) into
biliverdin, iron, and carbon monoxide (CO). Biliverdin is then directly converted into the antioxidant
bilirubin by biliverdin reductase (BVR), whilst iron gets scavenged by co-induced ferritin [11]. Heme
oxygenase activity causes resolution of inflammation. We and others previously demonstrated that
HO-activity is pivotal for reducing heme-induced vascular adhesion molecule expression and leukocyte
extravasation, whereas inhibition of HO-activity further increases adhesion molecules and leukocyte
influx [14,28,30,57–59].
The HO-effector molecules biliverdin/bilirubin, CO, and ferritin have each shown to be beneficial.
Bilirubin signaling mediates protection against a variety of inflammatory diseases [60]. Increasing
bilirubin has also been shown to increase the antioxidant capacity of the serum [61,62] and may protect
against the oxidative properties of heme in a similar fashion as ascorbic acid possibly improves the
condition of some COVID-19 patients [22].
Carbon monoxide signaling has been shown to protect the lung from inflammatory and oxidative
insults and modulates autophagy, mitochondrial biogenesis, apoptosis, and cellular proliferation. [63].
CO downregulates both innate and cell mediated immunity, and approaches with CO-releasing
molecules have been shown highly effective in animal models of T-cell mediated autoimmune
diseases [64,65]. Genetic polymorphisms determining the protective response against hemoglobin/heme
may contribute to differential disease outcomes. For example, a polymorphism in the HO-1 promoter
determines the level of HO-1 expression following stress [66–68]. Individuals with longer (GT)n
repeats have a lower transcriptional activity when compared to individuals with shorter (GT)n repeats,
and have lower HO-1 levels and less protection against inflammatory insults [67]. It would be
interesting to determine whether this differential protection by the antioxidant enzyme HO-1 has
impact on the clinical outcome of SARS-CoV-2 infection. In addition, haptoglobin polymorphisms may
result in more or less potent hemoglobin scavengers [69]. A decreased antioxidant capacity associated
with the Hp 2-2 isoform, results in an increased risk of heme-induced inflammatory complications [70].
4. How Can We Protect against the Injurious Actions of Free Heme During SARS-CoV-2 Infection?
Critically ill COVID-19 patients will often have excess of heme–proteins and heme in their
alveoli thereby fueling exudate formation, platelet activation, inflammation, and fibrosis (see Figure 1).
How can we prevent or attenuate these pulmonary complications?
Antioxidants 2020, 9, 540 4 of 11
Antioxidants 2020, 9, x FOR PEER REVIEW 4 of 11 
 
Figure 1. Heme-induced pulmonary complications following SARS-CoV-2 infection. Strategies to 
harness hemolysis-derived alveolar heme include administration of inducers of heme oxygenase 
(HO)-1 and hemoglobin (Hb)/heme scavengers (see green dashed box). “Proof of principle” studies 
should be performed to assess whether targeting heme by induction of HO-1 or administration of 
scavengers haptoglobin (hp)/hemopexin (hpx) can indeed attenuate or prevent complications in 
critically ill COVID-19 patients (see text for details). 
In a mouse model of ARDS, heme-induced pulmonary edema, endoplasmic reticulum stress, 
and fibrosis could be attenuated by intramuscular administration of the heme-scavenger hemopexin 
while lung function improved [17,33,71]. In addition, induction of HO-1 was shown to decrease 
heme-induced edema and inflammation in this and other models [11,28,30,57,71,72]. Hb and heme 
scavengers (hp and hpx, respectively), HO-1 induction, and HO-effector molecules have already 
demonstrated to mediate potent protection against heme-induced inflammation, thrombosis, and 
fibrosis in diverse diseases [13,14,53,73–81], whereas inhibition of HO-activity aggravates disease 
[28,82–84]. Administration of Hb/heme scavengers, induction of HO-1, or HO-effector molecules 
could thus be beneficial to prevent or treat the injurious actions of heme (see Figure 1). The 
cytoprotective enzyme HO-1 can be induced by a wide spectrum of agents, including aspirin, statins, 
probucol, valsartan, niacin, resveratrol, and curcumin that could be safely used in humans 
[11,73,83,85]. 
Alternatively, Nrf2 is a transcriptional factor that induces several antioxidant protective target 
genes, among which is HO-1. Dimethyl fumarate (DMF) is a clinically used Nrf2 activator [86] that 
could possibly be used to prevent the many heme-induced complications during SARS-CoV-2 
infection, such as edema, inflammation, and thrombosis and fibrosis by induction of the versatile 
HO-1 enzyme. Intriguingly, HO-1 induction and its effector molecules, CO and biliverdin/bilirubin, 
not only protect against inflammation, but have also potent antiviral properties that may be beneficial 
for fighting COVID-19 [87–95]. Preclinical in vitro and in vivo studies to eventual antiviral effects of 
Figure 1. Heme-induced pulmonary complications following SARS-CoV-2 infection. Strategies to
harness hemolysis-derived alveolar heme include administration of inducers of heme oxygenase (HO)-1
and hemoglobin (Hb)/heme scavengers (see green dashed box). “Proof of principle” studies should be
performed to assess whether targeting heme by induction of HO-1 or administration of scavengers
haptoglobin (hp)/hemopexin (hpx) can indeed attenuate or prevent complications in critically ill
COVID-19 patients (see text for details).
In a mouse model of ARDS, heme-induced pulmonary edema, endoplasmic reticulum stress, and
fibrosis could be attenuated by intramuscular administration of the heme-scavenger hemopexin while
lung function improved [17,33,71]. In addition, induction of HO-1 was shown to decrease heme-induced
edema and inflammation in this and other models [11,28,30,57,71,72]. Hb and heme scavengers
(hp and hpx, respectively), HO-1 induction, and HO-effector molecules have already demonstrated
to mediate potent protection against heme-induced inflammation, thrombosis, and fibrosis
in diverse diseases [13,14,53,73–81], whereas inhibition of HO-activity aggravates disease [28,82–84].
Administration of Hb/heme scavengers, induction of HO-1, or HO-effector molecules could thus be
beneficial to prevent or treat the injurious actions of heme (see Figure 1). The cytoprotective enzyme
HO-1 can be induced by a wide spectrum of agents, including aspirin, statins, probucol, valsartan,
niacin, resveratrol, and curcumin that could be safely used in humans [11,73,83,85].
Alternatively, Nrf2 is a transcriptional f ces several antioxidant protective target
gen s, among which is HO-1. Di et l ( F) is a clinically used Nrf2 activator [86] that
could possibly be used to prevent the many heme-induced complications during SARS-CoV-2 infection,
such as edema, inflammation, and thrombosis and fibr sis by induction of the versatile HO-1 enzyme.
Intriguingly, HO-1 induction and its effector molecules, CO and biliverdin/bilirubin, not only protect
against inflammation, but have also potent antiviral properties that may be beneficial for fighting
COVID-19 [87–95]. Preclinical in vitro and in vivo studies to eventual antiviral effects of HO1 inducers,
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bilirubin, or CO on Sars-CoV2 are thus warranted to better understand the possible translation of these
concepts to the clinical setting.
Obesity, diabetes, chronic kidney disease, cardiovascular diseases, COPD, male sex, and aging
form risk factors for developing severe complications when infected with SARS-CoV-2 [96–99].
These predisposing conditions, and inflammation in general, downregulate HO-1 expression and
activity [67,74,100–106], further supporting that this compromised protection and diminished tolerance
against inflammatory and oxidative stress promotes adverse clinical outcome in COVID-19 patients.
Recently, controversial and conflicting reports on possible associations between smoking and
COVID-19 survival were reported [107]. Initially, increased risk was reported [107], which could be
easily explained by the many well-established adverse health effects of smoking in, for instance, the lungs
and vasculature. Surprisingly, recent (prepublished reports) studies, however, suggest that smokers
may be under-represented among the COVID-19 patients with more severe disease. The smoking
prevalence was lower than expected among hospitalized patients in diverse countries, suggesting
that, counterintuitively, smoking could protect from severe complications [97,108–110]. This resulted
in immediate investigations to the putative protective effects of nicotine against COVID-19 [111].
Although interesting, another intriguing possibility is glooming: not nicotine but the increased vascular
carbon monoxide (CO) levels within smokers could possibly be the protective component. CO interacts
with hemoglobin to form carboxyhemoglobin, which is thereby protected from the release of debilitating
heme as previously also demonstrated for malaria [12].
Recently, the glucocorticoid dexamethasone was found to save many severely ill COVID-19
patients [112]. Since dexamethasone reduces hemolysis and induces HO-1 in macrophages [113], it is
tempting to speculate that this increased protection against free heme attenuates the severity of disease
in COVID-19 patients.
5. Conclusions
Until a vaccine against SARS-CoV-2 becomes available, we need to explore novel strategies to
attenuate the pro-inflammatory, pro-thrombotic, and pro-fibrotic consequences of SARS-CoV-2 leading
to morbidity and mortality. With this manuscript, we aimed to stress that heme is a likely culprit that
may play a relevant role in initiating and contributing to the pulmonary complications displayed in
critically ill COVID-19 patients. Inducing HO-1 expression or administration of Hb/heme scavengers
or HO-effector molecules may prevent SARS-CoV-2-induced pulmonary complications by its antiviral,
anti-inflammatory, antithrombotic, and antifibrotic activities. The heme-HO system represents an
interesting target for novel “proof of concept” studies in the context of COVID-19.
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